Finch’s FIN-524 is an investigational Rationally-Selected Microbiota product designed to treat ulcerative colitis.
FIN-524 is Finch’s first product candidate based on a rationally selected, synthetic ecology of microbes. FIN-524 leverages Finch’s Human-First Discovery platform, using a diversity of clinical datasets to identify the specific strains responsible for driving the promising efficacy observed with fecal microbiota transplantation in ulcerative colitis.
Finch and Takeda are collaborating to jointly develop FIN-524. The collaboration combines Finch’s unique discovery platform with Takeda’s strength in drug development for gastrointestinal diseases to advance this new class of microbial therapy.